Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Geovax Labs (NQ: GOVX )

1.450 +0.050 (+3.57%)
Streaming Delayed Price Updated: 3:59 PM EDT, May 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 28,903
Open 1.460
Bid (Size) 1.440 (16)
Ask (Size) 1.500 (6)
Prev. Close 1.400
Today's Range 1.420 - 1.538
52wk Range 0.2500 - 4.330
Shares Outstanding 2,172,309
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
GeoVax Presents Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Exposures COVID-19

Performance

YTD
+291.89%
+291.89%
1 Month
-26.02%
-26.02%
3 Month
+457.48%
+457.48%
6 Month
+192.93%
+192.93%
1 Year
+144.89%
+144.89%

More News

Read More
GeoVax Presents Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine
Via TheNewswire.com
Exposures COVID-19
GeoVax to Present Data on GEO-CM04S1, A Next Generation Covid-19 Vaccine, at the World Vaccine Congress
Via NewMediaWire
Exposures COVID-19
GeoVax to Present at the 36th Annual Roth Conference
Via NewMediaWire
GeoVax Labs, Inc. (NASDAQ: GOVX) Featured in Coverage of the 36th Annual Roth Conference
Via Investor Brand Network
Exposures COVID-19
GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing System
Via NewMediaWire
Geovax Labs: Q4 Earnings Insights
Via Benzinga
GeoVax Reports 2023 Year-End Financial Results and Provides Business Update
Via NewMediaWire
Exposures COVID-19
Earnings Scheduled For February 29, 2024
Via Benzinga
Earnings Outlook For Geovax Labs
Via Benzinga
InMed Pharmaceuticals And 2 Other Penny Stocks Insiders Are Buying
Via Benzinga
Topics Stocks
Exposures US Equities
GeoVax to Report 2023 Financial Results and Provide Corporate Update on February 29, 2024
Via NewMediaWire
GeoVax to Report 2023 Financial Results and Provide Corporate Update on February 29, 2024
Via TheNewswire.com
GeoVax to Present at the 2024 BIO CEO & Investor Conference
Via NewMediaWire
GeoVax to Present at the 2024 BIO CEO & Investor Conference
Via TheNewswire.com
GeoVax Announces Multiple Patent Issuances and Allowances
Via NewMediaWire
Topics Intellectual Property
Exposures Intellectual Property
GeoVax Reports Positive Interim Data From Phase 2 Clinical Trial of GEO-CM04S1 as a Universal Covid-19 Vaccine Booster
Via NewMediaWire
Exposures COVID-19
GeoVax Reports Positive Interim Data From Phase 2 Clinical Trial of GEO-CM04S1 as a Universal Covid-19 Vaccine Booster
Via TheNewswire.com
Exposures COVID-19
GeoVax Announces 1-for-15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement
Via NewMediaWire
GeoVax Announces 1-for-15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement
Via TheNewswire.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Via InvestorPlace
GeoVax Appoints Dr. Marc Pipas as Executive Medical Director, Oncology
Via NewMediaWire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.